Physician profile
Hamza Ansari
NPI 1548524812
$2,669.68
in general payments reported to CMS, 2019-2025
18 companies · $367 in 2025
The $367 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $131 · 2021: $233 · 2022: $386 · 2023: $346 · 2024: $912 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,625.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $476.72 | 2020-2024 | Impella |
| Abbott Laboratories | $456.29 | 2021-2025 | Aveir, Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Biosense Webster, INC. | $384.82 | 2024-2025 | Carto 3 |
| Cardiovascular Systems INC. | $297.64 | 2019-2022 | |
| Shockwave Medical, INC | $242.29 | 2021-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $122.59 | 2022-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $120.86 | 2024 | Uptravi, Opsumit |
| Boston Scientific Corporation | $99.02 | 2022-2025 | Bodyguardian |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $98.41 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $78.20 | 2021-2022 | |
| Edwards Lifesciences Corporation | $73.66 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Medtronic, INC. | $67.34 | 2022-2023 | Onyx Frontier |
| Philips North America LLC | $53.55 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.50 | 2023-2025 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $20.60 | 2023 | Evkeeza |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $12.98 | 2023 | |
| Medtronic Vascular, INC. | $12.31 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamza Ansari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.